KBC Group NV Sells 254 Shares of Krystal Biotech, Inc. $KRYS

KBC Group NV lowered its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 685 shares of the company’s stock after selling 254 shares during the period. KBC Group NV’s holdings in Krystal Biotech were worth $94,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after acquiring an additional 365,304 shares during the period. Braidwell LP grew its holdings in Krystal Biotech by 99.9% during the first quarter. Braidwell LP now owns 400,744 shares of the company’s stock valued at $72,254,000 after purchasing an additional 200,244 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Krystal Biotech by 3.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock valued at $45,168,000 after purchasing an additional 7,344 shares during the period. Nuveen LLC bought a new stake in Krystal Biotech in the first quarter valued at approximately $42,223,000. Finally, Woodline Partners LP raised its holdings in Krystal Biotech by 0.4% in the first quarter. Woodline Partners LP now owns 222,043 shares of the company’s stock worth $40,034,000 after purchasing an additional 941 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 3.8%

Shares of NASDAQ KRYS opened at $212.02 on Friday. The company has a fifty day moving average price of $186.30 and a 200 day moving average price of $156.75. The firm has a market cap of $6.15 billion, a PE ratio of 31.79 and a beta of 0.65. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $214.72.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $1.54. The firm had revenue of $97.80 million for the quarter, compared to the consensus estimate of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. Equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

KRYS has been the subject of several research analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a report on Monday, September 15th. Bank of America boosted their target price on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Citigroup increased their price target on Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Finally, Guggenheim set a $224.00 price objective on Krystal Biotech and gave the company a “buy” rating in a report on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Krystal Biotech has an average rating of “Moderate Buy” and a consensus price target of $228.14.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).